Douglas E. Platt
CEO
CardioQuip, LLC
8422 Calibration Ct.
College Station , TX 77845
United States
dplatt@cardioquip.comFEI 3007899424Issued Feb 11, 2022Center for Devices and Radiological Health
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3007899424.
Violations11
Issue DateFeb 11, 2022
Product TypeMedical Devices
StatusOpen
Letter Details
Firm
CardioQuip, LLC
Location
Douglas E. Platt
CEO
CardioQuip, LLC
8422 Calibration Ct.
College Station , TX 77845
United States
dplatt@cardioquip.com
FEI Number
3007899424
Country
United States
Issue Date
February 11, 2022
Issuing Office
Center for Devices and Radiological Health
Product Type
Medical Devices
Status
Open
Summary
CardioQuip, LLC manufactured cardiac heater-cooler devices that underwent significant design and component modifications since their original 510(k) clearance in 2010, including the addition of an airflow hood, dripless external hose kit, and thermoelectric cooling technology, without obtaining the required new clearances or demonstrating substantial equivalence. The company failed to comply with Current Good Manufacturing Practice (CGMP) and Quality System Regulation (QSR) requirements, and the modifications to the device design, components, and manufacturing methods constituted significant changes that should have triggered new premarket notification submissions under 21 CFR 807.81(a)(3). An FDA investigator documented these violations during an inspection conducted from August 19 through September 17, 2021 at the firm's College Station, Texas facility.
CardioQuip, LLC FDA Warning Letter, February 11, 2022